2010
DOI: 10.1016/j.biopsych.2010.04.039
|View full text |Cite
|
Sign up to set email alerts
|

Adjunctive Intranasal Oxytocin Reduces Symptoms in Schizophrenia Patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

7
215
2
2

Year Published

2011
2011
2022
2022

Publication Types

Select...
7
2
1

Relationship

1
9

Authors

Journals

citations
Cited by 280 publications
(226 citation statements)
references
References 16 publications
7
215
2
2
Order By: Relevance
“…The current links between OXT and DA and the pronounced effects over tasks in the social domain mean that OXT is of particular interest to clinical groups. 125 Preliminary studies have shown its potential efficacy in patients with schizophrenia [126][127][128] and autism 129 and have shown behavioural effects in patients with schizophrenia, 130,131 depression, 32 generalized anxiety disorder 28,29 and autism. 132 Importantly, the prosocial effects of OXT may offer potential for synergistic pharmacotherapeutic and psychotherapeutic treatments of these severe disorders.…”
Section: Resultsmentioning
confidence: 99%
“…The current links between OXT and DA and the pronounced effects over tasks in the social domain mean that OXT is of particular interest to clinical groups. 125 Preliminary studies have shown its potential efficacy in patients with schizophrenia [126][127][128] and autism 129 and have shown behavioural effects in patients with schizophrenia, 130,131 depression, 32 generalized anxiety disorder 28,29 and autism. 132 Importantly, the prosocial effects of OXT may offer potential for synergistic pharmacotherapeutic and psychotherapeutic treatments of these severe disorders.…”
Section: Resultsmentioning
confidence: 99%
“…As oxytocin and vasopressin systems contribute to different aspects of brain physiology in different species thus having a role in speciestypical social behaviors (Goodson, 2013), it is important to sample from a wide variety of animal systems to get a broad picture of both the potential and limitations of these systems in humans. The ability to translate appropriately across species and developmental time points becomes imperative as the enthusiasm grows for intranasal oxytocin and vasopressin therapies in various developmental disabilities and mental illness (Guastella et al, 2009(Guastella et al, , 2010Andari et al, 2010;Feifel et al, 2010;Goldman et al, 2011;Pedersen et al, 2011;Simeon et al, 2011;Hall et al, 2012). In addition to gathering data from a wide variety of species, it will be important to understand the behavioral context in which oxytocin and vasopressin function.…”
Section: Discussionmentioning
confidence: 99%
“…Interestingly, the AVPR1a receptor of the closely related nonapeptide vasopressin has also been associated with ASD [40][41][42]. This provisional role of OT in ASD, is further supported by two linkage studies [43,44], clinical evidence by several groups demonstrating clinical improvement in ASD following OT administration [45][46][47][48][49][50][51] (also see [52,53]) and studies showing that ASD is also associated with alterations in OT plasma levels [54].…”
Section: Oxytocin and Autism Spectrum Disorders (Asd)mentioning
confidence: 91%